AKT3 overexpression

We established MIA-GEM cells, a PDAC cell line resistant to gemcitabine (GEM), a first-line anticancer drug, using the human PDAC cell line-MIA-PaCa-2...Elevated MAST4 expression correlated with a poorer prognosis in PDAC. Consequently, nuclear MAST4 emerges as a potential marker for GEM resistance and poor prognosis, representing a novel therapeutic target for PDAC.

Degrader 12l potently suppressed the growth of H1975OR as well as several NSCLC cell lines with low nanomolar IC values and demonstrated promising in vivo antitumor efficacy in nude mice bearing H1975OR or PC9 NSCLC xenograft models. Selective degradation of Akt3 may be considered as a novel strategy for human cancer therapy.

Circ_0011232 facilitated HCC progression via miR-503-5p/AKT3 axis, which might provide a novel treatment strategy for HCC.

CircWHSC1 accelerated malignancy and glycolysis of TNBC cells by the miR-212-5p/AKT3 axis. The research provided a potential prognostic biomarker and therapeutic target for TNBC.

Circ_0016760 played an oncogenic role to promote the proliferation, migration, and invasion and restrained the apoptosis of NSCLC cells via miR-646/AKT3 signaling.